Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med1995; 333:1581–7.
2.
LydenPD (ed). Thrombolytic Therapy for Stroke. Totowa, NJ: Humana Press, 2001.
3.
StewartRJFredenburghJCLeslieBAKeytBARischkeJAWeitzJI. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J Biol Chem2000; 275:10112–20.
4.
VerstraeteM. Third Generation Thrombolytic Drugs. Am J Med2000; 109:52–8.
5.
KeytBAPaoniNFRefinoCJ. A faster acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA1994; 91:3670.
6.
CannonCPGibsonCMMcCabeCS. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocrdial infarction. Circulation1998; 98:2805.
7.
CollenDStassenJYasudaT. Comparative thrombolytic properties of tissue-type plasminogen activator and of plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost1994; 72:98.
8.
ThomasGRThibodeauxHErrettCJ. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding. Stroke1994; 25:2072.
9.
BenedictCRRefinoCJKeytBA. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation1995; 92:3032.
LapchakPA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res2010; 1:96–107.
12.
LapchakPAAraujoDMZivinJA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol2004; 185:154.
13.
ChapmanDFLydenPLapchakPANunezSThibodeauxHZivinJ. Comparison of TNK with wild-type tissue plasminogen activator in a rabbit embolic stroke model. Stroke2001; 32:748.
14.
CannonCPMcCabeCSGibsonCM. TNK-tissue plasminogen activator in acute myocardial infarction. Circulation1997; 95:351.
15.
Van de WerfFCannonCPLuytenA. Safety assessment of single bolus administration of TNK-tPA in acute myocardial infarction: the ASSENT-1 trial. Am Heart J1999; 137:786.
16.
Van De WerfFAdgeyJArdissinoD. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet1999; 354:716–22.
17.
Van de WerfFBarronHVArmstrongPW. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents. Eur Heart J2001; 22:2253.
18.
HaleyECJrLydenPDJohnstonKCHemmenTM. A pilot dose-escalation safety study of tenecteplase in acute ischemic stroke. Stroke2005; 36:607–12.
19.
HaleyECJrThompsonJLGrottaJC. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke2010; 41:707–11.
20.
ParsonsMWMiteffFBatemanGA. Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window. Neurology2009; 72:915–21.
